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Memorial Sloan-Kettering Cancer Center from 1949 to
1972.1 This previous study investigated the distinguish-
ing characteristics associated with a favorable progno-
sis after treatment of lung cancer. Not unexpectedly,
stage proved to be the most important determinant of
long-term survival.
Our current study was prompted by our interest in
A lthough there is considerable published informationabout the natural history of non–small cell lung
cancer within the first 5 years after resection, there is
relatively little information about the long-term survival
of such patients beyond 5 years.
The first retrospective analysis of 10-year survivors
after treatment of lung cancer covered the experience at
Objective: The purpose of this study was to determine (in survivors of 5
years after resection of their lung cancer) whether age, sex, histologic
condition, and age have any influence on furthering survival beyond 5
years. Methods: From 1973 to 1989, 686 patients were alive and well 5
years after complete resection of their lung cancers. Survival analysis
was carried out with only deaths from lung cancer treated as deaths.
Deaths from other causes were treated as withdrawals. Multivariate Cox
regression was used to test the relationship of survival to age, sex, histo-
logic condition, and stage. Results: The population in this study had the
following characteristics at the time of operation: The male/female ratio
was 1.38:1, and the median age was 61 years. The histologic condition of
their lung cancer was adenocarcinoma in 412 patients, squamous cell in
244 patients, large cell carcinoma in 29 patients, and small cell carcino-
ma in 1 patient. The stage of the disease was stage IA in 263 patients, IB
in 261 patients, IIA in 12 patients, IIB in 68 patients, and IIIA in 82
patients. The extent of resection was a lobectomy or bilobectomy in 579
patients, pneumonectomy in 55 patients, and wedge resection or segmen-
tectomy in 52 patients. A recurrence or a new lung primary occurrence
was considered as failure to remain free of lung cancer. The median fol-
low-up on all patients was 122 months from initial treatment. Of the 686
patients, 26 patients experienced the development of late recurrence and
36 new cancers, beyond 5 years. Overall survival for 5 additional years
after a 5-year check point was 92.4%. Likewise, survival by nodal status
was 93% for N0 tumors, 95% for N1 tumors, and 90% for N2 tumors.
Survival by stage was 93% for stage I tumors and 91% for stage II or
IIIA tumors. Conclusions: In patients with surgically treated lung cancer,
neither age, sex, histologic condition, nor stage is a predictor of the risk
of late recurrence or new lung cancer. The only prognostic factor appears
to be the survival of the patient free of lung cancer for 5 years from the
initial treatment, with a resultant favorable outlook to remain well for 10
or more years. (J Thorac Cardiovasc Surg 1999;117:32-8)
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finding out what the risks of recurrence or new lung
primary occurrence are in patients who are free of dis-
ease 5 or more years from surgical treatment of their
initial cancer.
The study focused on the 5-year survivors free of
cancer and covered the patients treated by resection for
stages I, II, and IIIA disease at our center. Those
patients with stage IIIB or IV disease were excluded
because they are generally not offered an operation.
The objectives were to determine in survivors of 5
years after resection whether there were differences in
survival by lymph node status at initial presentation;
whether age, sex, or histologic condition had any influ-
ence on furthering survival beyond 5 years; and what
the frequency of recurrence, if any, was beyond 5 years.
Patients and methods
From 1973 to 1989, 1490 patients underwent complete
resection of lung cancer. Of these, 686 patients (46%) were
seen by us 5 years after the treatment and were free of cancer.
This included patients with pathologic stage I, II, and IIIA
tumors and represented 59% of all patients treated by com-
plete resection at our center during that time period for stage I
cancer, 25% of stage II cancer, and 29% of stage IIIA cancer.
At thoracotomy, the extent of intrathoracic disease was
carefully assessed with particular reference to regional lymph
nodes (N1 or N2). A complete resection of all disease in the
lung was performed in all patients, and a mediastinal lymph
node dissection was performed in most of the patients.
Postoperative pathologic staging was done after the resected
specimen was reviewed histologically, and all regional nodes
were assessed. Histologic type, tumor location, tumor size,
histologic clearance at bronchial and vascular resection mar-
gins, and visceral pleural involvement were recorded. The
surgical and pathologic reports of all patients were reviewed
to ensure that the resection was complete.
We defined local recurrence as evidence of tumor within
the same lung or at the bronchial stump, regional recurrence
as clinically or radiologically manifest disease in the medi-
astinum or in supraclavicular nodes, and distant recurrence
as disease in the contralateral lung or outside the hemithorax.
Except in instances where different histologic conditions
were present, our guidelines to define second lung primary
occurrences were as follows: We recognized a second lung
lesion as a new primary even if a tumor of the same histo-
logic condition was found in a different lobe or lung and all
regional nodes (N1 or N2) were free of tumor (Table I).3,4 In
squamous carcinomas, the presence of in situ change in the
respective lobar or segmental bronchus suggested a new lung
primary occurrence even if found in the same lobe. Because
of the frequency of multicentric presentations in broncho-
alveolar carcinoma, this subset was excluded from consider-
ation of multiple lung primaries unless the second lesion
appeared 2 or more years after the initial resection and no
lymph node metastasis was found at the initial surgical treat-
ment or at the time of appearance of the presumed second
primary.
To avoid controversy about recurrence or a new lung pri-
mary occurrence, we analyzed both groups and considered
them failures to remain free of lung cancer.
Survival was calculated by the Kaplan-Meier method,5
including postoperative deaths and all lung cancer–related
deaths. All other deaths were treated as withdrawals.
Differences in survival were determined by the log-rank test
and difference in frequency data by the c 2 test. Multivariate
Cox regression6 was used to test the relationship of survival
to age, sex, histologic condition, and stage. Age was treated
as a continuous variable; sex was treated as a categoric vari-
able and histologic condition was treated as a categoric vari-
able with 3 classes, which are adenocarcinoma, squamous
carcinoma, and others (Table II). Stage was used as an ordi-
nal variable with 3 possible values (Table III).
Results
There were 398 male patients and 288 female
patients. The age range at initial treatment was 19 to 87
years, with a median age of 61 years. There were 120
patients (17%) who were 70 years of age or older and
17 patients who were younger than 40 years of age. All
Table I. Criteria for diagnosis of multiple lung cancers
Metachronous tumors
Histologic type different
Histologic type the same, if:
Free interval between cancers is at least 2 years or
Origin from carcinoma in situ or
Second cancer in different lobe or lung, but:
No carcinoma in lymphatics common to both
No extrapulmonary metastases at time of diagnosis
Synchronous tumors
Tumors physically distinct and separate
Histologic type
Different
Same, but in different segment, lobe, or lung, if:
Origin from carcinoma in situ
No carcinoma in lymphatics common to both
No extrapulmonary metastases at time of diagnosis
Table II. Histologic condition at the time of the diag-
nosis of lung cancer
Cell type Number (%)
Adenocarcinoma 412 (60)
Adenocarcinoma 328
Bronchoalveolar carcinoma 84
Squamous carcinoma 244 (36)
Large cell carcinoma 29 (4)
Small cell carcinoma 1 (<1)
Total 686 (100)
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patients had a Karnofsky performance status of 80% or
better.7
The extent of pulmonary resection consisted of a
lobectomy or bilobectomy in 84% of patients, a pneu-
monectomy in 8% of patients, and lesser resections in
the remaining patients (Table IV).
The histologic condition was adenocarcinoma in
60% of patients, squamous cell carcinoma in 36% of
patients, and large cell carcinoma in 4% of patients
(Table II).
On the basis of the new international staging system
for lung cancer published in June 1997,7,8 76% of the
patients had stage I disease; 12% of the patients had
stage II disease, and 12% of the patients had stage IIIA
disease (Table III). Of the 74 patients with stage IIIA
(N2) disease, 61 patients were treated initially with
complete resection, and 13 patients received induction
therapy before complete resection.
Incidence of recurrence or new lung cancers after
treatment of the initial cancer. Of 686 patients, 33
patients had recurrences before they survived to 5
years. All 33 patients were rendered disease free. Of
these, 20 recurrences were at distant sites, 5 were local
recurrences, 7 were regional recurrences, and 1 was
unspecified. Fourteen of the distant recurrences were
solitary brain metastases, of which 12 were resected
and 2 were treated by external radiation therapy only.
Two distant recurrences were in the buttock and were
treated by resection and postoperative external radia-
tion therapy. Two metastases in the ilium and spine
were treated with external radiation therapy. One
metastasis in an inguinal node was excised, and 1
metastasis in the lung was treated by intraoperative
interstitial implantation of iodine 125. Two of the local
recurrences were in the lung and were treated by resec-
tion. One bronchial lung recurrence, 2 chest wall recur-
rences, and 7 regional metastases into mediastinal or
cervical lymph nodes were treated by external radiation
therapy. The site of the recurrence or its treatment was
not specified in one patient. Of the 33 patients in whom
a recurrence had developed and had been rendered dis-
ease free before 5 years, 28 patients remained free of
cancer, and 5 patients had additional recurrences after
5 years and died despite treatment.
Multiple lung cancers were seen and treated in 28
patients (11 synchronous, 17 metachronous) before
they attained their 5-year survival free of disease. All
were treated by surgical resection.
Incidence of recurrence and new lung primary
after 5 years. There were 36 patients in whom new
lung cancers developed after 60 months. Of these, 23
patients have died of the new cancers, 10 patients are
alive and well, 2 patients are alive with disease from
the new lung cancer, and 1 patient has died of an unre-
lated cause.
A total of 26 patients had late recurrences after 60
months. Of these, 24 patients have died of the disease,
and 2 are alive with the disease. Recurrences were local
in 3 patients, regional in 3 patients, local and regional
in 2 patients, and distant in 18 patients. Of the distant
metastases, 9 metastases were in the brain, 3 metas-
tases were in the lung, 2 metastases were in bone, 2
metastases were in the liver, and 2 metastases were in
bones and lungs. 
Survival at or after 10 years. Of the 686 patients
who had survived 5 years and were free of disease, 369
patients were followed up for an additional 5 years. Of
these 289 patients (78%) were still alive free of cancer,
an additional 58 patients (16%) died subsequently of
unrelated causes, 18 patients died of disease, and 4
patients were alive with disease.
Multivariable Cox regression showed that age (P =
.70), sex (P = .37), histologic condition (P = .42), stage
(P = .36), and the likelihood ratio analysis (significance
level, .29) provided evidence that none of the variables
used had significantly influenced survival. There was a
Table III. Pathologic stage after the initial treatment
Number Total (%)
Stage I 524 (76)
IA (T1 N0) 263
IB (T2 N0) 261
Stage II 80 (12)
IIA (T1 N1) 12
IIB (T2 N1) 43
IIB (T3 N0) 25
Stage IIIA 82 (12)
IIIA (T3 N1) 8
IIIA (T1-3 N2) 74
Total 686 (100)
Table IV. Extent of pulmonary resection at initial
treatment
Treatment Number
Lobectomy 509
Sleeve lobectomy 12
Bilobectomy 58
Pneumonectomy 55
Wedge resection 45
Segmentectomy 7
Total 686
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persistent although somewhat diminishing incidence of
new lung primaries despite survivals of up to 20 or
more years. However, the incidence of late recurrences
diminished more noticeably with time.
The overall 10-year survival (Kaplan-Meier) of the
patients who were cancer free at 5 years was 92.4%
(Fig 1). Of the 686 patients, 445 patients (65%) were
alive and disease free at the time of this reporting, 177
patients (26%) had died of unrelated causes, and 60
patients had died of either late recurrence or a new lung
primary occurrence plus 4 patients who were alive with
disease (total, 9%). For patients who were alive and
well 5 years after treatment of the initial lung cancer,
the probabilities of survival beyond 5 years were excel-
lent, irrespective of the nodal status (Fig 2) or stage of
disease at initial presentation (Fig 3).
Discussion
Most reports in the literature on survival after treat-
ment of non–small cell lung cancer are calculated from
the date of diagnosis or initial treatment.1,10,12-15 Infor-
mation regarding the risks of recurrence or new lung
primary occurrences after a survival free of disease of
5 or more years are sparse and focus mainly on resect-
ed stage I lung cancers.
This study focused on patients who were alive with
no evidence of disease 5 years after complete resec-
tion of lung cancer. It presents estimates of survival
and incidence of recurrence and new primary occur-
rences for patients who are disease free at 5 years.
The dependence of survival on age, sex, histologic
condition, and initial stage was also analyzed. None
of these characteristics had any significant effect on
additional survival.
Patients with stage I or II disease are generally offered
resection as their primary mode of treatment, and most
long-term survivors fall into these 2 groups. Although
involvement of the mediastinal nodes (N2) or direct
extension of the tumor into the chest wall, diaphragm,
or mediastinum (T3) is considered a more advanced
Fig 1. Overall survival (95% confidence limits at 10 years, 89.9% to 94.5%).
Fig 2. Survival by nodal status.
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stage of disease, 74 patients with stage IIIA (N2) dis-
ease and 33 patients with T3 N0-1 M0 tumors were free
of cancer at 5 years from their initial surgical treatment.
We have considered a new lung tumor detected after
a complete and potentially curative resection of a lung
cancer, as a new cancer and not a metastasis, if the free
interval between cancers was at least 2 years and all
regional nodes (N1 and N2) were negative for tumor.
This may have favored in our analysis a greater inci-
dence of new primary occurrences over recurrences.
Nevertheless, we felt that any new lung lesion repre-
sented failure to control lung cancer.
In the current review, an interesting case was discov-
ered in which recurrence developed 14 years after
resection of a stage I bronchoalveolar carcinoma. The
patient had multiple pulmonary metastases documented
by thoracoscopic biopsy and remains alive 5 years later
without treatment.
Although several publications have addressed long-
term survival in lung cancer,10-18 3 major articles have
been recently published on the incidence of late recur-
rences and new lung primary occurrences. One was the
report by the Lung Cancer Study Group,15,19,20 the sec-
ond from the Mayo Clinic,21 and the third from our
center.2 All 3 publications addressed this subject in
stage I lung cancers only, whereas the current review
addresses, in addition, patients with stage II or IIIa dis-
ease, treated by complete resection. Our results indi-
cate that neither age, sex, histologic condition, nor
stage is a determinant of risk of late recurrence or new
lung cancer. There was no significant difference in the
incidence of late recurrence between patients with
stage I tumor and those with stage II or III disease.
Importantly, recurrences beyond 5 years were usually
fatal whereas one third of the patients who experienced
the development of new lung primary occurrences sur-
vived with treatment.
We recognize that survival from initial diagnosis and
treatment of a lung cancer is stage dependent, that sur-
gical treatment is best in stage I or II disease, and that
combined modality therapy is essential in the locally
advanced tumors. However, despite presumed effective
surgical treatment, we are faced with failures to control
the cancer mostly because of distant metastases. This is
less so in stage I disease and more so in stages II and
III tumors. Nevertheless, those patients who remain
well for 5 years seem to have a favorable outlook
because the vast majority of patients (92%) do not die
of lung cancer thereafter. Because second primary can-
cers exceed recurrence after 5 years, the need for con-
tinued surveillance and consideration of chemopreven-
tion for this group of patients is emphasized.
Our conclusions are that (1) once the patients survive
beyond 5 years, there is no difference in survival
between N0, N1, and N2 (the disease behaves the same
after 5 years); (2) neither age, sex, nor histologic con-
dition further influences the 10-year survival; (3) late
recurrences are infrequent; and (4) second primary
lung cancers continue to pose a threat although their
incidence is also reduced with time.
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Discussion
Dr Mark K. Ferguson (Chicago, Ill). This paper is typical
of the thoroughly analyzed and data-laden work that has been
produced by the Memorial group for the past 25 years. Dr
Martini and his colleagues have chosen to address important
issues centered around the long-term outcome of 5-year sur-
vivors after resection for lung cancer. 
As far as I can determine from my review of the literature,
these data are unique and quite important. They found that
subsequent survival was excellent and was unrelated to stage,
nodal status, or sex. The likelihood of cancer recurrence after
5 years was 8%, and after 10 years the recurrence rate was
less than 5%. These are important findings that suggest that,
from a practical perspective, the 5-year interval is insufficient
to declare that a patient with lung cancer may be cured.
I performed a similar analysis of long-term survival of
patients receiving operations at the University of Chicago.
Our patients were nearly identical to those at Memorial in
terms of their age at the time of operation. In our patients, the
mean duration of follow-up was similar to that of the
Memorial group, 105 months compared with their follow-up
of 122 months. Our data support those of the Memorial group
in that there was no difference in survival after 5 years,
regardless of stage, nodal status, or sex. However, there was
a striking difference in the 10-year survival data, which was
only 64% compared with a 10-year survival in the Memorial
data of about 92%. 
Their 10-year survival figure is substantially higher than
what would be predicted by a life table analysis, which I cal-
culate to be closer to the range of 80% rather than in excess
of 90%. Therefore my first statement concerns the survival
calculations you have presented. 
They suggest that you have a group of patients who have a
history of cancer and who also presumably have an extensive
smoking history, but who nevertheless appear to have a better
long-term probability of survival than the average population
at that age. 
My second question addresses the issue of when we can
consider a patient with lung cancer to have been cured. There
is already considerable controversy about the appropriate
interval for patient follow-up and the type of subsequent test-
ing that should be performed for patients with lung cancer.
From the data you presented regarding the low incidence of
cancer recurrence at 5 years, I submit that this may be a rea-
sonable threshold to permit the declaration of a cancer cure.
However, you recommend continued follow-up and further
investigation of chemo-prevention techniques for these
patients. What specifically do you propose we do about
patient follow-up after the 5-year time interval in terms of
examination interval and testing, and what information do
you have that suggests such follow-up is cost effective?
Dr John R. Benfield (Sacramento, Calif). As you know,
one of the ongoing discussions in the treatment of lung can-
cer is the role of limited resection as compared with standard
lobectomy. I do not wish to get into that today except to say
that one of the main issues of contention is the significance of
local recurrence. In your group of patients who did have
recurrence, and I recognize that that is a relatively small num-
ber, there must be a subset of patients who had local recur-
rence only. To what degree did local recurrence only lead to
death?
Dr Martini. Dr Ferguson, these patients were not selected
by us. They were treated by us and presented to us 5 years
later free of cancer. So there was no preselection. For what-
ever reason, some patients with advanced cancer remain free
of disease indefinitely, despite their poor prognosis initially.
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As to the best continued surveillance beyond 5 years, I
really do not know the right answer. Cost effectiveness is also
an unknown factor. Many believe that it is not cost effective
to follow any potentially cured lung cancer after the opera-
tion. I do not subscribe to that. I think that once a person has
been affected by lung cancer, it is wise to have that patient
followed up at least on a yearly interval to rule out recurrence
or new cancers.
Dr Benfield, I am not an advocate of a lesser resection
than a lobectomy, no matter how small the lesion is and
how early it has been detected. The only instance in our
review in which there was a failure of control of the disease
was in patients who had a second or a third primary lung
cancer, when necessarily the surgeon had opted to do a
lesser resection. In those patients there was evidence of
local recurrence.
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